Reaction
Rectal Ulcer reporting signals
As of the last recalculation, Rectal Ulcer appears in 1,160 FAERS reports alongside 13 co-occurring drug terms. The strongest observed disproportionality signal is SEVELAMER CARBONATE (PRR 23.7).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sevelamer Carbonate | 15 | 23.7 | 23.7 |
| Meperidine Hydrochloride | 9 | 17.7 | 17.7 |
| Desoximetasone | 13 | 12.4 | 12.4 |
| Infliximab-Dyyb | 19 | 11.8 | 11.8 |
| Vedolizumab | 48 | 10.4 | 10.4 |
| Bevacizumab | 56 | 8.5 | 8.5 |
| Atezolizumab | 16 | 7.5 | 7.5 |
| Erlotinib | 4 | 7.4 | 7.4 |
| Erlotinib Hydrochloride | 5 | 7.2 | 7.2 |
| Dabigatran Etexilate Mesylate | 23 | 5.8 | 5.8 |
| Lenvatinib | 9 | 5.0 | 5.0 |
| Methoxy Polyethylene Glycol-Epoetin Beta | 3 | 4.9 | 4.9 |
| Cabozantinib | 12 | 4.5 | 4.5 |